Αποτελέσματα Αναζήτησης
The Indian pharmaceutical industry is poised for growth. Even at current rates of seven to eight percent CAGR, the industry’s annual revenues can grow to about USD 80 to 90 billion by 2030.
1 Απρ 2016 · The article provides an industry analysis and the strategies adopted by the Indian Pharmaceutical companies to engineer growth primarily through generics, biosimilars and formulations.
The Indian pharmaceutical industry is the world’s 3rd largest by volume and 14th largest in terms of value. Total Annual Turnover of Pharmaceuticals was Rs. 2,89,998 crore for the year 2019-2020.
The Indian pharma industry has grown at a compounded growth rate of (CAGR) of ~11% in the domestic market and ~16% in exports over the last two decades. While the domestic market has grown at a similar pace to the gross domestic product (GDP), the overall growth has been driven by the industry’s leadership in supplying generic formulations to
PHARMACEUTICAL SECTOR IN INDIA 12. India’s pharmaceutical growth trajectory has been spectacular in the last few decades. From being a net importer of drugs in the 1970s to becoming one of the major exporters of drugs and vaccines, India now ranks third and thirteenth globally in terms of volume and value,12 respectively. From a
The Indian Pharmaceutical Market (IPM) is one of the fastest growing markets globally, growing at a rate of 10% per annum*, despite recent impact of demonetization and GST roll-out.
India’s GVA continues to record healthy growth On the supply side, gross value added (GVA) grew 7.0% last fiscal, as per provisional estimates (compared with 8.8% in fiscal 2022).
